Co-Founder at Foundation Institute for 21st Century Medicine; Founding Partner and Chief Scientist at Medicxi; Executive Chairman at RxCelerate
Following an academic career at Cambridge University spanning 20 years, leading a world-renowned group investigating the biology of chronic inflammation, David joined Index Ventures as a Venture Partner, before co-founding leading European Venture Capital house Medicxi in 2015. He is now Chief Scientific Advisor to Medicxi, while creating new biotech companies, together with Richard Mason, at the Foundation Institute for 21st Century Medicine, based at Babraham Research Campus. David is also co-Founder Executive Chairman at RxCelerate Group, a rapidly-growing provider of out-sourced drug development services to the pharmaceutical industry, with more than 40 staff also based at Babraham Research Campus. David has more than 70 academic publications in journals including Nature, Science & Nature Medicine, is an inventor on more than one hundred patents, and founded more than 20 biotech companies, including Funxional Therapeutics (sold to Boehringer Ingelheim in 2012) and XO1 (sold to Janssen in 2015). As DrugBaron, David is also a well-known blogger with Forbes, and writes extensively on drug discovery and development.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557